Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ONXX -- Ignore unavailable to you. Want to Upgrade?

To: Marc Bertoglio who wrote (190)	5/7/1998 8:44:00 AM
From: C. K. Humphries	Read Replies (1) \| Respond to of 810

Marc, I'm not surprised that the short interest is low. Word has it that Rothschild bought in at about $7. There has been a nice steady progression over the last few weeks. I think the insider smart money is getting on board. I bought another 600 shares yesterday. This isn't ENMD but I hope it could double on good news. The Onyx 015 product supposedly kills cancer without any side effects-painless chemotherapy. If it is working and the drug is moving on to phase III, we may see that $25 target reached. The genetic based therapies are in vogue this month. Counting the days until ASCO. I hope I'm right. Kent